• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Letter: optimising response to ustekinumab therapy for patients with Crohn's disease-author's reply.

作者信息

Kopylov Uri

机构信息

Department of Gastroenterology, Sheba Medical center, Tel Hashomer, Israel.

出版信息

Aliment Pharmacol Ther. 2020 Sep;52(5):907. doi: 10.1111/apt.15974.

DOI:10.1111/apt.15974
PMID:32852835
Abstract
摘要

相似文献

1
Letter: optimising response to ustekinumab therapy for patients with Crohn's disease-author's reply.信件：优化克罗恩病患者对优特克单抗治疗的反应——作者回复
Aliment Pharmacol Ther. 2020 Sep;52(5):907. doi: 10.1111/apt.15974.
2
Letter: optimising response to ustekinumab therapy for patients with Crohn's disease.信函：优化克罗恩病患者对乌司奴单抗治疗的反应
Aliment Pharmacol Ther. 2020 Sep;52(5):906. doi: 10.1111/apt.15961.
3
Higher Drug Exposure During the First 24 Weeks of Ustekinumab Treatment Is Associated With Endoscopic Remission in Crohn's Disease.优特克单抗治疗的前24周内较高的药物暴露量与克罗恩病的内镜缓解相关。
Clin Gastroenterol Hepatol. 2023 Mar;21(3):838-840.e2. doi: 10.1016/j.cgh.2021.12.020. Epub 2021 Dec 20.
4
An indirect comparison of ustekinumab and vedolizumab in the therapy of TNF-failure Crohn's disease patients.优特克单抗与维多珠单抗治疗肿瘤坏死因子治疗失败的克罗恩病患者的间接比较
J Comp Eff Res. 2018 Feb;7(2):101-111. doi: 10.2217/cer-2017-0041. Epub 2017 Nov 8.
5
Letter: effectiveness of ustekinumab or vedolizumab in Crohn's disease following anti-TNF failure-getting closer to the truth. Authors' reply.
Aliment Pharmacol Ther. 2020 Oct;52(7):1255-1256. doi: 10.1111/apt.16062.
6
Ustekinumab-Induced Remission of Two Cases of Refractory Cutaneous Crohn's Disease.优特克单抗诱导两例难治性皮肤克罗恩病缓解
Inflamm Bowel Dis. 2021 Oct 18;27(10):e124. doi: 10.1093/ibd/izab115.
7
Letter: potential selection bias in real-world comparison of ustekinumab versus vedolizumab as a second-line treatment for Crohn's disease-authors' reply.信件：优特克单抗与维多珠单抗作为克罗恩病二线治疗药物的真实世界比较中的潜在选择偏倚——作者回复
Aliment Pharmacol Ther. 2022 Apr;55(8):1070-1071. doi: 10.1111/apt.16896.
8
Letter: ustekinumab for the treatment of post-surgical and refractory Crohn's disease.信函：优特克单抗用于治疗术后及难治性克罗恩病。
Aliment Pharmacol Ther. 2021 Apr;53(7):859-860. doi: 10.1111/apt.16281.
9
Real-world Short-term Effectiveness of Ustekinumab in Crohn's Disease: Results from a Multicenter, Prospective Study in China.乌司奴单抗在中国克罗恩病中的真实世界短期疗效：一项多中心前瞻性研究结果
Inflamm Bowel Dis. 2022 Jun 2;28(Suppl 2):S42-S44. doi: 10.1093/ibd/izac078.
10
Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.用于诱导克罗恩病缓解的抗IL-12/23 p40抗体。
Cochrane Database Syst Rev. 2015 May 5(5):CD007572. doi: 10.1002/14651858.CD007572.pub2.